Evidence map›Paper›PMID 25969699›Full record

ArticleAlzheimer's research & therapy2015

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.

Kristin Harkins, Pamela Sankar, Reisa Sperling, Joshua D Grill, Robert C Green, Keith A Johnson, Megan Healy, Jason Karlawish

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 2 pooled it
36.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Psychosocial implications of learning amyloid PET results in an observational cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Observational
  14. Amyloid PET disclosure in subjective cognitive decline: Patient experiences over time.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  15. Reasons for undergoing amyloid imaging among diverse enrollees in the A4 study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  16. Article
  17. Post-disclosure distress among racial and ethnic groups in a preclinical AD trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Kristin HarkinsDepartment of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA.
Pamela SankarDepartment of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA.
Reisa SperlingDepartment of Neurology, Harvard Medical School, Center for Alzheimer Research and Treatment, Brigham & Women's Hospital Massachusetts ADRC, Massachusetts General Hospital, Boston, MA USA.
Joshua D GrillMary S. Easton Center for Alzheimer's Disease Research, University of California Los Angeles, Los Angeles, CA USA.
Robert C GreenDepartment of Medicine, Division of Genetics, Brigham & Women's Hospital and Harvard Medical School, Boston, MA USA.
Keith A JohnsonDepartments of Neurology and Radiology, Harvard Medical School, Center for Alzheimer Research and Treatment, Brigham & Women's Hospital Massachusetts ADRC, Massachusetts General Hospital, Boston, MA USA.
Megan HealyDepartment of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA.
Jason KarlawishDepartments of Medicine, Medical Ethics & Health Policy, University of Pennsylvania Perelman School of Medicine, Penn Neurodegenerative Disease Ethics & Policy Program, University of Pennsylvania, 3615 Chestnut St, Philadelphia, PA 19104 USA.
University of Pennsylvania · USBrigham and Women's Hospital · USHarvard University · USUniversity of California, Los Angeles · US

Funding

RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
NIA NIH HHS P30 AG010124NIA NIH HHS P30 AG062421NIA NIH HHS P50 AG005134NIA NIH HHS U19 AG010483
6 · The paper itself

Abstract

introductionThe objective of this study was to develop a process to maximize the safety and effectiveness of disclosing Positron Emission Tomography (PET) amyloid imaging results to cognitively normal older adults participating in Alzheimer's disease secondary prevention studies such as the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Study.

methodsUsing a modified Delphi Method to develop consensus on best practices, we gathered and analyzed data over three rounds from experts in two relevant fields: informed consent for genetic testing or human amyloid imaging.

resultsExperts reached consensus on (1) text for a brochure that describes amyloid imaging to a person who is considering whether to undergo such imaging in the context of a clinical trial, and (2) a process for amyloid PET result disclosure within such trials. Recommendations included: During consent, potential participants should complete an educational session, where they receive verbal and written information covering what is known and unknown about amyloid imaging, including possible results and their meaning, implications of results for risk of future cognitive decline, and information about Alzheimer's and risk factors. Participants should be screened for anxiety and depression to determine suitability to receive amyloid imaging information. The person conducting the sessions should check comprehension and be skilled in communication and recognizing distress. Imaging should occur on a separate day from consent, and disclosure on a separate day from imaging. Disclosure should occur in person, with time for questions. At disclosure, investigators should assess mood and willingness to receive results, and provide a written results report. Telephone follow-up within a few days should assess the impact of disclosure, and periodic scheduled assessments of depression and anxiety, with additional monitoring and follow-up for participants showing distress, should be performed.

conclusionsWe developed a document for use with potential study participants to describe the process of amyloid imaging and the implications of amyloid imaging results; and a disclosure process with attention to ongoing monitoring of both mood and safety to receive this information. This document and process will be used in the A4 Study and can be adapted for other research settings.

Identifiers

PMID25969699
PMCPMC4428104
OpenAlexW2120450971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.